The potential role of miRNA therapies in spinal muscle atrophy

Spinal muscular atrophy (SMA) is a neurodegenerative disease caused by low levels of full-length survival motor neuron (SMN) protein due to the loss of the survival motor neuron 1 (SMN1) gene and inefficient splicing of the survival motor neuron 2 (SMN2) gene, which mostly affects alpha motor neuron...

Full description

Bibliographic Details
Main Authors: Gandhi, Gayatri, Abdullah, Syahrilnizam, Foead, Agus Iwan, Yeo, Wendy Wai Yeng
Format: Article
Language:English
Published: Elsevier BV 2021
Online Access:http://psasir.upm.edu.my/id/eprint/95562/1/The%20potential%20role%20of%20miRNA%20therapies%20in%20spinal%20muscle%20atrophy.pdf
_version_ 1796983121369890816
author Gandhi, Gayatri
Abdullah, Syahrilnizam
Foead, Agus Iwan
Yeo, Wendy Wai Yeng
author_facet Gandhi, Gayatri
Abdullah, Syahrilnizam
Foead, Agus Iwan
Yeo, Wendy Wai Yeng
author_sort Gandhi, Gayatri
collection UPM
description Spinal muscular atrophy (SMA) is a neurodegenerative disease caused by low levels of full-length survival motor neuron (SMN) protein due to the loss of the survival motor neuron 1 (SMN1) gene and inefficient splicing of the survival motor neuron 2 (SMN2) gene, which mostly affects alpha motor neurons of the lower spinal cord. Despite the U.S. Food and Drug Administration (FDA) approved SMN-dependent therapies including Nusinersen, Zolgensma® and Evrysdi™, SMA is still a devastating disease as these existing expensive drugs may not be sufficient and thus, remains a need for additional therapies. The involvement of microRNAs (miRNAs) in SMA is expanding because miRNAs are important mediators of gene expression as each miRNA could target a number of genes. Hence, miRNA-based therapy could be utilized in treating this genetic disorder. However, the delivery of miRNAs into the target cells remains an obstacle in SMA, as there is no effective delivery system to date. This review highlights the potential strategies for intracellular miRNA delivery into target cells and current challenges in miRNA delivery. Furthermore, we provide the future prospects of miRNA-based therapeutic strategies in SMA.
first_indexed 2024-03-06T11:01:55Z
format Article
id upm.eprints-95562
institution Universiti Putra Malaysia
language English
last_indexed 2024-03-06T11:01:55Z
publishDate 2021
publisher Elsevier BV
record_format dspace
spelling upm.eprints-955622022-08-02T07:12:09Z http://psasir.upm.edu.my/id/eprint/95562/ The potential role of miRNA therapies in spinal muscle atrophy Gandhi, Gayatri Abdullah, Syahrilnizam Foead, Agus Iwan Yeo, Wendy Wai Yeng Spinal muscular atrophy (SMA) is a neurodegenerative disease caused by low levels of full-length survival motor neuron (SMN) protein due to the loss of the survival motor neuron 1 (SMN1) gene and inefficient splicing of the survival motor neuron 2 (SMN2) gene, which mostly affects alpha motor neurons of the lower spinal cord. Despite the U.S. Food and Drug Administration (FDA) approved SMN-dependent therapies including Nusinersen, Zolgensma® and Evrysdi™, SMA is still a devastating disease as these existing expensive drugs may not be sufficient and thus, remains a need for additional therapies. The involvement of microRNAs (miRNAs) in SMA is expanding because miRNAs are important mediators of gene expression as each miRNA could target a number of genes. Hence, miRNA-based therapy could be utilized in treating this genetic disorder. However, the delivery of miRNAs into the target cells remains an obstacle in SMA, as there is no effective delivery system to date. This review highlights the potential strategies for intracellular miRNA delivery into target cells and current challenges in miRNA delivery. Furthermore, we provide the future prospects of miRNA-based therapeutic strategies in SMA. Elsevier BV 2021-08 Article PeerReviewed text en http://psasir.upm.edu.my/id/eprint/95562/1/The%20potential%20role%20of%20miRNA%20therapies%20in%20spinal%20muscle%20atrophy.pdf Gandhi, Gayatri and Abdullah, Syahrilnizam and Foead, Agus Iwan and Yeo, Wendy Wai Yeng (2021) The potential role of miRNA therapies in spinal muscle atrophy. Journal of the Neurological Sciences, 427. pp. 117485-117495. ISSN 0022-510X; ESSN: 1878-5883 https://www.sciencedirect.com/science/article/pii/S0022510X21001799?via%3Dihub 10.1016/j.jns.2021.117485
spellingShingle Gandhi, Gayatri
Abdullah, Syahrilnizam
Foead, Agus Iwan
Yeo, Wendy Wai Yeng
The potential role of miRNA therapies in spinal muscle atrophy
title The potential role of miRNA therapies in spinal muscle atrophy
title_full The potential role of miRNA therapies in spinal muscle atrophy
title_fullStr The potential role of miRNA therapies in spinal muscle atrophy
title_full_unstemmed The potential role of miRNA therapies in spinal muscle atrophy
title_short The potential role of miRNA therapies in spinal muscle atrophy
title_sort potential role of mirna therapies in spinal muscle atrophy
url http://psasir.upm.edu.my/id/eprint/95562/1/The%20potential%20role%20of%20miRNA%20therapies%20in%20spinal%20muscle%20atrophy.pdf
work_keys_str_mv AT gandhigayatri thepotentialroleofmirnatherapiesinspinalmuscleatrophy
AT abdullahsyahrilnizam thepotentialroleofmirnatherapiesinspinalmuscleatrophy
AT foeadagusiwan thepotentialroleofmirnatherapiesinspinalmuscleatrophy
AT yeowendywaiyeng thepotentialroleofmirnatherapiesinspinalmuscleatrophy
AT gandhigayatri potentialroleofmirnatherapiesinspinalmuscleatrophy
AT abdullahsyahrilnizam potentialroleofmirnatherapiesinspinalmuscleatrophy
AT foeadagusiwan potentialroleofmirnatherapiesinspinalmuscleatrophy
AT yeowendywaiyeng potentialroleofmirnatherapiesinspinalmuscleatrophy